The U.S. Food and Drug Administration approved Eli Lilly and Co.’s Reyvow, representing the first new class of acute migraine treatment approved by the regulatory agency in more than two decades.
As GlaxoSmithKline continues to evolve the company’s business structure under Chief Executive Officer Emma Walmsley, another leadership change occurred as Jack Bailey – head of the U.S. pharmaceuticals business – is stepping down at the end of 2019.
Alameda, Calif.-based Exelixis inked a collaboration, option and license deal with India’s Aurigene Discovery Technologies Ltd., which focuses on oncology and inflammatory diseases.
Merck & Co. Inc. agreed to buy privately held Tilos Therapeutics for up to $773 million, bolstering the drugmaker‘s pipeline to treat cancer and autoimmune diseases.
Singapore-based ASLAN Pharmaceuticals amended the company’s global license agreement with CSL Limited to gain full rights to the fully human monoclonal antibody ASLAN004 being developed for atopic dermatitis and other inflammatory diseases.
Sumitomo Dainippon Pharma Co. Ltd. and Poxel SA announced the signing of a strategic partnership for the development and commercialization of Imeglimin – an investigational therapeutic agent for type 2 diabetes – in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. Poxel is a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders.
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
Zymeworks and GSK Enter Second Strategic Collaboration to Develop and Commercialize Bi-Specific Antibodies VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc., a leader in the development of bi-specific and multi-specific antibodies and […]
No pain, no gain. Shareholders in Gilead Sciences (GILD 6.78%) may want to repeat that workout mantra as they watch markets slide. True, Gilead has taken some lumps. It was […]
LONDON— GlaxoSmithKline GSK -3.47 % PLC is selling its remaining rights to a drug for use in treating autoimmune diseases, including multiple sclerosis, to Novartis AG NVS -3.07 % for […]
